RxDoctor Payments Data

Diana Williford

Psychiatric/Mental Health · Waco, TXNPI 1497535967

Payments from drug & device makers

$2,892in general payments, 2019–2025

Across 158 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$637
  • Otsuka America Pharmaceutical, Inc.$452
  • Teva Pharmaceuticals USA, Inc.$440
  • AbbVie$436
  • Neurocrine Biosciences, Inc.$397
  • Alkermes, Inc.$226
  • plus $303 from 3 others

What the payments were for

  • Food & beverage$2,78196%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,892 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$8,309
Medicare patients
25
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate22$67,321
AustedoDeutetrabenazine14$62,979
RexultiBrexpiprazole25$36,081
TrintellixVortioxetine Hydrobromide12$6,292
Aripiprazole90$3,934
Duloxetine Hcl202$2,910
Hydroxyzine Pamoate154$2,489
Buspirone Hcl167$2,423
Quetiapine Fumarate119$2,202
Haloperidol Decanoate37$1,988
Ziprasidone Hcl43$1,926
Paliperidone ErPaliperidone19$1,758
Oxcarbazepine49$1,571
Prazosin Hcl87$1,369
Benztropine Mesylate105$1,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$142$67,32122 claims
Teva Pharmaceuticals USA, Inc.Austedo$440$62,97914 claims
Otsuka America Pharmaceutical, Inc.Rexulti$452$36,08125 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$6,29212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →